Can Journavx (suzetrigine) be used as part of a multimodal analgesic regimen for adults undergoing total knee arthroplasty, and what is the recommended dosing and safety considerations?

Journavx for Total Knee Arthroplasty

Yes, Journavx (suzetrigine) can be used as part of a multimodal analgesic regimen for adults undergoing total knee arthroplasty (TKA), offering a non-opioid alternative that provides clinically meaningful pain relief without CNS side effects or addiction potential. 1

Indication and Mechanism

Journavx is FDA-approved for moderate to severe acute pain in adults 1. It works by selectively inhibiting NaV1.8 voltage-gated sodium channels in peripheral pain-sensing neurons, blocking pain signal transmission without crossing the blood-brain barrier 2, 3. This peripheral-only mechanism eliminates opioid-related concerns including respiratory depression, sedation, dependence, and addiction 2.

Dosing Protocol for TKA

Initial dose: 100 mg orally on an empty stomach (at least 1 hour before or 2 hours after food) to avoid delayed onset. Clear liquids (water, apple juice, vegetable broth, tea, black coffee) are permitted during this fasting period 1.

Maintenance dosing: Starting 12 hours after the initial dose, give 50 mg orally every 12 hours. These doses can be taken with or without food 1.

Duration: Use for the shortest duration consistent with pain control goals. Clinical studies have not evaluated use beyond 14 days 1.

Integration with Multimodal Analgesia

Current AAOS guidelines strongly recommend COX-2 selective NSAIDs and acetaminophen as foundational components of multimodal analgesia for TKA to limit opioid use and improve function 4. Journavx fits naturally into this framework as an additional non-opioid option. The 2022 AAOS guideline also supports perioperative IV ketamine for decreased opioid consumption in the first 24 hours 4.

Practical algorithm:

• Layer 1 (baseline): Scheduled COX-2 inhibitor + acetaminophen 4
• Layer 2 (moderate-severe pain): Add Journavx 100 mg initial dose, then 50 mg q12h 1
• Layer 3 (breakthrough only): Short-acting opioid as rescue, not scheduled
• Perioperative adjunct: Consider single-dose IV ketamine in first 24 hours 4

Critical Safety Considerations

Drug Interactions - Absolute Contraindications

Do not use with strong CYP3A inhibitors (contraindicated) 1. Examples include:

• Ketoconazole, itraconazole, clarithromycin, ritonavir

Reduce dose with moderate CYP3A inhibitors: Give initial 100 mg dose, then only doses 2-4 at 50 mg q12h, then reduce to 50 mg every 24 hours for subsequent doses 1.

Hormonal Contraceptive Interactions

Journavx induces CYP3A, potentially reducing contraceptive efficacy 1. Patients on hormonal contraceptives containing progestins other than levonorgestrel or norethindrone must use additional non-hormonal contraception (condoms) or switch to alternative methods during treatment and for 28 days after discontinuation 1.

Hepatic Impairment

• Severe hepatic impairment (Child-Pugh C): Avoid use 1
• Moderate hepatic impairment (Child-Pugh B): Give initial 100 mg dose, then doses 2-4 at 50 mg q12h, then reduce to 50 mg every 24 hours 1
• Mild hepatic impairment (Child-Pugh A): No dose adjustment needed 1

Avoid Grapefruit

Grapefruit products inhibit CYP3A and should be avoided during treatment 1.

Adverse Event Profile

Phase 3 trials in 874 patients showed Journavx was well-tolerated with predominantly mild-to-moderate adverse events 1, 5:

Common adverse reactions (>1% and greater than placebo):

• Pruritus (2.1% vs 1.6% placebo)
• Muscle spasms (1.3% vs 0.5%)
• Increased CPK (1.1% vs 0.5%)
• Rash (1.1% vs 0.5%)

Nausea/vomiting rates were lower than opioids: 9-20% with Journavx vs 16-33% with hydrocodone/acetaminophen 1.

Laboratory monitoring considerations:

• CPK elevations >3x ULN occurred in 2.9% (vs 1.2% placebo) but were asymptomatic and required no intervention 1
• eGFR decreases ≥25% occurred in 2.5% (vs 0.9% placebo) and appeared to resolve after discontinuation 1

Discontinuation rate: Only 0.6% discontinued due to adverse events (postprocedural hematoma, hypotension, syncope) 1.

Clinical Efficacy Evidence

Phase 3 trials demonstrated statistically significant and clinically meaningful pain reduction versus placebo in post-surgical acute pain 5:

• After abdominoplasty: SPID48 difference of 48.4 points (P<0.0001)
• After bunionectomy: SPID48 difference of 29.3 points (P=0.0002)
• Time to 2-point pain reduction: 119-240 minutes vs 480 minutes with placebo

Pain reduction was similar to hydrocodone/acetaminophen but without CNS effects or addiction risk 5. A broader phase 3 single-arm study in 256 patients with various surgical and non-surgical acute pain conditions showed 83.2% rated effectiveness as good, very good, or excellent 6.

Key Clinical Pitfalls to Avoid

1. Don't give first dose with food - delays onset of action; ensure empty stomach for initial 100 mg dose 1
2. Screen for CYP3A inhibitors - check medication list before prescribing; strong inhibitors are contraindicated 1
3. Address contraception proactively - counsel women of childbearing age about need for backup contraception 1
4. Don't use in severe hepatic impairment - check liver function if cirrhosis suspected 1
5. Swallow tablets whole - do not crush or chew 1